SEC 13F Intelligence

Managers / Q2 2022 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$1.6B
Q2 2022
Positions
76
Filings on Record
27
2019–present window
Filed
Aug 15, 2022
original filing

Summary

Boxer Capital, LLC reported $1.6B in U.S.-listed holdings across 76 positions for Q2 2022.

Its largest position, MRTXEUR, represents 8.5% of the portfolio.

Compared with Q1 2022, the fund opened 5 new positions and exited 3.

Portfolio Metrics

Turnover
+7.2%
vs prior filed quarter
Top-10 Concentration
+42.1%
share of reported value
Largest Position
+8.5%
Mirati Therapeutics
New / Exited
5 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 77.9%Other: 14.1%ADR: 5.7%ETP: 2.4%Equity WRT: 0.0%
  • Common Stock · 77.9% · $1.2B
  • Other · 14.1% · $222M
  • ADR · 5.7% · $90M
  • ETP · 2.4% · $37M
  • Equity WRT · 0.0% · $88,000

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SRPTSarepta Therapeutics IncNEW+200.0K200.0K+$15M$15M
Ascendis Pharma A/SNEW+70.0K70.0K+$7M$7M
ETNBGBP89Bio IncNEW+1.40M1.40M+$5M$5M
COGTCogent Biosciences IncNEW+425.0K425.0K+$4M$4M
MREOMereo Biopharma Group PLCNEW+2.25M2.25M+$3M$3M
RAREUltragenyx Pharmaceutical IncSOLD OUT−200.0K0−$15M$0
Odonate Therapeutics IncSOLD OUT−4.21M0−$6M$0
GNCAQGenocea Biosciences IncSOLD OUT−1.13M0−$1M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

75 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMirati Therapeutics Inchistory →COM8.50%$134M2.00M
2CYTKCytokinetics Inchistory →COM NEW5.23%$83M2.10M
3ONCBeiGene Ltdhistory →SPONSORED ADR5.13%$81M500.0K
4RVMDRevolution Medicines Inchistory →COM4.30%$68M3.48M
5APLSUSDApellis Pharmaceuticals Inchistory →COM3.73%$59M1.30M
6SWTXUSDSpringworks Therapeutics Inchistory →COM3.24%$51M2.08M
7PMVPPMV Pharmaceuticals Inchistory →COM3.16%$50M3.50M
8Prometheus Biosciences IncCOM3.06%$48M1.71M
9TYRATyra Biosciences Inchistory →COM2.92%$46M6.45M
10RLAYRelay Therapeutics Inchistory →COM2.83%$45M2.67M
112662247DiTeos Therapeutics Inchistory →COM2.81%$44M2.15M
12Merus N VCOM2.72%$43M1.90M
13Turning Point Therapeutics ICOM2.72%$43M570.7K
14AMLXAmylyx Pharmaceuticals Inchistory →COM2.68%$42M2.20M
15RETAEURReata Pharmaceuticals Inchistory →CL A2.38%$38M1.24M
16SPDR SER TRS&P BIOTECH2.35%$37M500.0K
17RCUSArcus Biosciences Inchistory →COM2.30%$36M1.43M
18SG7Sage Therapeutics Inchistory →COM2.24%$35M1.09M
19TNGXTango Therapeutics Inchistory →COM1.97%$31M6.87M
20IDYAIdeaya Biosciences Inchistory →COM1.93%$30M2.20M
21BLUBellus Health Inc Newhistory →COM NEW1.87%$30M3.20M
22ANABAnaptysBio Inchistory →COM1.67%$26M1.30M
232655787DBlueprint Medicines Corphistory →COM1.62%$26M507.4K
24AM6Amicus Therapeutics Inchistory →COM1.58%$25M2.33M
25KNTEUSDKinnate Biopharma Inchistory →COM1.48%$23M1.85M
26IOVAIovance Biotherapeutics Inchistory →COM1.35%$21M1.94M
27DAWNGBXDay One Biopharmaceuticalshistory →COM1.35%$21M1.19M
28GOSSGossamer Bio Inchistory →COM1.31%$21M2.46M
29RCKTRocket Pharmaceuticals Inchistory →COM1.28%$20M1.47M
30XENEXenon Pharmaceuticals Inchistory →COM1.16%$18M600.0K
31ACADAcadia Pharmaceuticals Inchistory →COM1.13%$18M1.26M
32Point Biopharma Global IncCOM1.08%$17M2.50M
33NUVLNuvalent Inchistory →COM1.04%$16M1.21M
34RNAGBPAvidity Biosciences Inchistory →COM1.03%$16M1.12M
35NRIXNurix Therapeutics Inchistory →COM0.98%$16M1.22M
36SRPTSarepta Therapeutics Inchistory →COM0.95%$15M200.0K
37BMEABiomea Fusion Inchistory →COM0.90%$14M1.19M
38NUVBNuvation Bio IncCOM CL A · *W EXP 07/07/2020.90%$14M4.61M
39CGEMCullinan Oncology Inchistory →COM0.87%$14M1.07M
40MISTMilestone Pharmaceuticals Inhistory →COM0.87%$14M2.24M
41FATEFate Therapeutics Inchistory →COM0.78%$12M500.0K
42GH Research PLCORDINARY SHARES0.64%$10M1.01M
43Prothena Corp PLCSHS0.52%$8M300.0K
44AKROAkero Therapeutics IncCOM0.50%$8M831.5K
45Rain Therapeutics IncCOM0.41%$7M1.18M
46Ascendis Pharma A/SSPONSORED ADR0.41%$7M70.0K
47NGM Biopharmaceuticals IncCOM0.41%$6M500.0K
48260Centessa Pharmaceuticals PLCSPONSORED ADS0.39%$6M1.25M
49TSVT*2Seventy Bio IncCOMMON STOCK0.38%$6M459.8K
50DBV Technologies S ASPONSORED ADR0.34%$5M2.13M
51BDTXBlack Diamond Therapeutics ICOM0.31%$5M2.01M
52BCLS Acquisition CorpCOM CL A0.31%$5M500.0K
53Theseus Pharmaceuticals IncCOM0.31%$5M892.1K
54Panacea Acquisition Corp IICL A SHS0.31%$5M500.0K
55ORICOric Pharmaceuticals IncCOM0.30%$5M1.05M
56EQRx IncCOM0.30%$5M1.00M
57ETNBGBP89Bio IncCOM0.29%$5M1.40M
58Selecta Biosciences IncCOM0.27%$4M3.28M
59Health Sciences Acq Corp 2ORD SHS0.25%$4M400.0K
60Atreca IncCL A COM0.25%$4M2.20M
61COGTCogent Biosciences IncCOM0.24%$4M425.0K
62Solid Biosciences IncCOM0.21%$3M5.34M
63MREOMereo Biopharma Group PLCADS0.16%$3M2.25M
6432WCodiak Biosciences IncCOM0.16%$2M850.1K
65EPIEUREssa Pharma IncCOM NEW0.14%$2M724.5K
66Gemini Therapeutics IncCOM0.14%$2M1.30M
67Omega Alpha SPACCL A0.12%$2M200.0K
68BCABGBPBioAtla IncCOM0.12%$2M686.3K
69Aligos Therapeutics IncCOM0.12%$2M1.53M
70MEI Pharma IncCOM NEW0.11%$2M2.91M
71Elevation Oncology IncCOM0.08%$1M872.8K
72TARAProtara Therapeutics IncCOM STK0.04%$613,000209.2K
73CABACabaletta Bio IncCOM0.04%$572,000540.0K
74BLCMEURBellicum Pharmaceuticals IncCOM NEW0.00%$68,00057.0K
75SRZNWSurrozen IncW EXP 08/01/2030.00%$13,00066.7K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.